公开(公告)号：US20250092036A1

公开(公告)日：2025-03-20

申请号：US18800559

申请日：2024-08-12

Applicant: Novartis AG

Inventor： Erich W. BAUM ,  Thomas A. DINEEN, JR. ,  Jonathan Edward HEMPEL ,  Matthew James HESSE ,  Robert KOENIG ,  Matthew James LAMARCHE ,  Jay Francis LARROW ,  Ruowei MO ,  Henrik MOEBITZ ,  Rukundo NTAGANDA ,  Keith Bruce PFISTER ,  Martin SENDZIK ,  Colin Keith SKEPPER ,  Joseph WZOREK, JR. ,  Frédéric ZECRI

IPC: C07D471/04 ,  A61K31/454 ,  A61K31/4545 ,  A61P35/00 ,  C07D401/06 ,  C07D405/14 ,  C07D491/052

Abstract: The invention relates to compounds which modulate the activity of ERK. The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by ERK.

公开(公告)号：US20210323956A1

公开(公告)日：2021-10-21

申请号：US17268512

申请日：2019-08-12

Applicant: Novartis AG

Inventor： Christopher ADAIR ,  Katsumasa NAKAJIMA ,  Rukundo NTAGANDA ,  Julien PAPILLON ,  Troy Douglas SMITH

IPC: C07D417/12 ,  A61K45/06

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.